etaracizumab etaracizumab etaracizumab, also known as medi-522, trade name abegrin, is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer, ovarian cancer and various other types of cancer. it is manufactured by medimmune. etaracizumabmonoclonal antibodytypewhole antibodysourcehumanized (from mouse)targetalpha-v beta-3 integrinclinical datatrade namesabegrinatc codenoneidentifierscas number892553-42-3 nchemspidernoneunii41w9mfi160keggd09342 ychemical and physical dataformulac6392h9908n1732o1996s42molar mass144302.22 g·mol−1 ny (what is this?) (verify) it is an enhanced iteration of vitaxin, also known as medi-523. both are derived from the mouse antibody lm609.